streptomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, produced by Streptomyces strains | 2481 | 57-92-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antibiotic produced by the soil actinomycete Streptomyces griseus. It acts by inhibiting the initiation and elongation processes during protein synthesis.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 55 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 34.39 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.34 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.78 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.65 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 4.30 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 18, 1946 | FDA | PFIZER |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Paradoxical drug reaction | 64.60 | 36.14 | 13 | 503 | 4139 | 63484367 |
| Drug reaction with eosinophilia and systemic symptoms | 62.09 | 36.14 | 19 | 497 | 33817 | 63454689 |
| Drug resistance | 38.30 | 36.14 | 12 | 504 | 22921 | 63465585 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Paradoxical drug reaction | 128.39 | 47.30 | 27 | 881 | 3324 | 34952699 |
| Drug resistance | 92.78 | 47.30 | 32 | 876 | 25895 | 34930128 |
| Immune reconstitution inflammatory syndrome | 79.07 | 47.30 | 22 | 886 | 8737 | 34947286 |
| Tuberculoma of central nervous system | 77.69 | 47.30 | 12 | 896 | 252 | 34955771 |
| Immune reconstitution inflammatory syndrome associated tuberculosis | 64.20 | 47.30 | 11 | 897 | 447 | 34955576 |
| Pathogen resistance | 51.17 | 47.30 | 16 | 892 | 9466 | 34946557 |
| Hepatitis cholestatic | 49.62 | 47.30 | 15 | 893 | 7932 | 34948091 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Paradoxical drug reaction | 185.38 | 38.37 | 39 | 1358 | 7146 | 79735845 |
| Drug resistance | 124.96 | 38.37 | 41 | 1356 | 42172 | 79700819 |
| Immune reconstitution inflammatory syndrome associated tuberculosis | 89.07 | 38.37 | 15 | 1382 | 821 | 79742170 |
| Immune reconstitution inflammatory syndrome | 86.72 | 38.37 | 24 | 1373 | 13817 | 79729174 |
| Tuberculoma of central nervous system | 79.92 | 38.37 | 13 | 1384 | 574 | 79742417 |
| Pathogen resistance | 67.93 | 38.37 | 20 | 1377 | 14322 | 79728669 |
| Drug reaction with eosinophilia and systemic symptoms | 60.16 | 38.37 | 27 | 1370 | 64217 | 79678774 |
| Drug-induced liver injury | 56.27 | 38.37 | 26 | 1371 | 66091 | 79676900 |
| Conductive deafness | 44.80 | 38.37 | 7 | 1390 | 238 | 79742753 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A07AA04 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Antibiotics |
| ATC | A07AA54 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Antibiotics |
| ATC | J01GA01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE AMINOGLYCOSIDE ANTIBACTERIALS Streptomycins |
| ATC | J04AM01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis |
| FDA CS | M0000946 | Aminoglycosides |
| FDA EPC | N0000175477 | Aminoglycoside Antibacterial |
| FDA EPC | N0000175483 | Antimycobacterial |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D011500 | Protein Synthesis Inhibitors |
| CHEBI has role | CHEBI:33281 | antibiotics |
| CHEBI has role | CHEBI:36043 | antimicrobial drugs |
| CHEBI has role | CHEBI:36047 | antibacterial drugs |
| CHEBI has role | CHEBI:48001 | protein synthesis inhibitors |
| CHEBI has role | CHEBI:86328 | anti-fungal agrichemical |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tularemia | indication | 19265001 | |
| Acute tuberculosis | indication | 25629007 | |
| Granuloma inguinale | indication | 28867007 | DOID:9113 |
| Plague | indication | 58750007 | DOID:3482 |
| Klebsiella cystitis | indication | 60867007 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Brucellosis | indication | 75702008 | DOID:11077 |
| Pulmonary tuberculosis | indication | 154283005 | DOID:2957 |
| Chancroid | indication | 266143009 | DOID:13778 |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Proteus urinary tract infection | indication | 301012009 | |
| Bacterial urinary infection | indication | 312124009 | |
| Aerobic Gram-Negative Bacteremia | indication | ||
| Synergy for Streptococcal Endocarditis | indication | ||
| Haemophilus Endocarditis | indication | ||
| Synergy for Enterococcal Endocarditis | indication | ||
| Enterococcus Urinary Tract Infection | indication | ||
| Synergy for Enterococcal Infections | indication | ||
| H. Influenzae Meningitis | indication | ||
| Pulmonary Mycobacterium avium complex infection | off-label use | 186342000 | |
| Hypocalcemia | contraindication | 5291005 | |
| Parkinsonism | contraindication | 32798002 | |
| Dehydration | contraindication | 34095006 | |
| Tinnitus | contraindication | 60862001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Pregnancy, function | contraindication | 289908002 | |
| Vertigo | contraindication | 399153001 | |
| Inner Ear Disturbance | contraindication | ||
| Disorder of the 8th Cranial Nerve | contraindication | ||
| Infant Botulism | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Bacterial enteritis caused by Escherichia coli | Indication |
| Cattle | Bacterial enteritis caused by Salmonella spp | Indication |
| Chickens | Nonspecific infectious enteritis caused by bacteria | Indication |
| Swine | Bacterial enteritis caused by Escherichia coli | Indication |
| Swine | Bacterial enteritis caused by Salmonella spp | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Entromycin Powder | Zoetis Inc. | 2 |
| STREP SOL | Huvepharma EOOD | 1 |
| Streptomycin Oral Solution | Huvepharma EOOD | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.43 | acidic |
| pKa2 | 12.62 | acidic |
| pKa3 | 13.36 | acidic |
| pKa4 | 13.79 | acidic |
| pKa5 | 11.91 | Basic |
| pKa6 | 11.21 | Basic |
| pKa7 | 6.49 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 30S ribosomal protein S12 | Ribosomal protein | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019933 | VUID |
| N0000148018 | NUI |
| D01350 | KEGG_DRUG |
| 3810-74-0 | SECONDARY_CAS_RN |
| 4017475 | VANDF |
| 4019933 | VANDF |
| C0038425 | UMLSCUI |
| CHEBI:58007 | CHEBI |
| SRY | PDB_CHEM_ID |
| CHEMBL372795 | ChEMBL_ID |
| CHEMBL453087 | ChEMBL_ID |
| CHEMBL3184791 | ChEMBL_ID |
| D013307 | MESH_DESCRIPTOR_UI |
| DB01082 | DRUGBANK_ID |
| 10923 | IUPHAR_LIGAND_ID |
| 3685 | INN_ID |
| Y45QSO73OB | UNII |
| 19649 | PUBCHEM_CID |
| 10109 | RXNORM |
| 1794 | MMSL |
| 5514 | MMSL |
| d00159 | MMSL |
| 002770 | NDDF |
| 004895 | NDDF |
| 387223008 | SNOMEDCT_US |
| 40877002 | SNOMEDCT_US |
| 73246001 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Streptomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0706 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 21 sections |
| Streptomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0706 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 21 sections |
| Streptomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0706 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 21 sections |
| Streptomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0706 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 21 sections |